Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 55.2 CHF 1.28% Market Closed
Market Cap: 669.1m CHF

Wall Street
Price Targets

BSLN Price Targets Summary
Basilea Pharmaceutica AG

Wall Street analysts forecast BSLN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BSLN is 80.92 CHF with a low forecast of 64.64 CHF and a high forecast of 110.25 CHF.

Lowest
Price Target
64.64 CHF
17% Upside
Average
Price Target
80.92 CHF
47% Upside
Highest
Price Target
110.25 CHF
100% Upside
Basilea Pharmaceutica AG Competitors:
Price Targets
SYNACT
SynAct Pharma AB
11% Upside
AUPH
Aurinia Pharmaceuticals Inc
4% Upside
IMDX
Insight Molecular Diagnostics Inc
23% Upside
MRUS
Merus NV
3% Upside
BAVA
Bavarian Nordic A/S
35% Upside
KRYS
Krystal Biotech Inc
9% Downside
NTLA
Intellia Therapeutics Inc
136% Upside
KNSA
Kiniksa Pharmaceuticals Ltd
33% Upside

Revenue
Forecast

Revenue Estimate
Basilea Pharmaceutica AG

For the last 13 years the compound annual growth rate for Basilea Pharmaceutica AG's revenue is 9%. The projected CAGR for the next 4 years is 3%.

9%
Past Growth
3%
Estimated Growth
Estimates Accuracy
3%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Basilea Pharmaceutica AG

The compound annual growth rate of Basilea Pharmaceutica AG's operating income for the next 4 years is -33%.

N/A
Past Growth
-33%
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Net Income
Forecast

Net Income Estimate
Basilea Pharmaceutica AG

The compound annual growth rate of Basilea Pharmaceutica AG's net income for the next 4 years is -36%.

N/A
Past Growth
-36%
Estimated Growth
Estimates Accuracy
-38%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BSLN's stock price target?
Price Target
80.92 CHF

According to Wall Street analysts, the average 1-year price target for BSLN is 80.92 CHF with a low forecast of 64.64 CHF and a high forecast of 110.25 CHF.

What is Basilea Pharmaceutica AG's Revenue forecast?
Projected CAGR
3%

For the last 13 years the compound annual growth rate for Basilea Pharmaceutica AG's revenue is 9%. The projected CAGR for the next 4 years is 3%.

What is Basilea Pharmaceutica AG's Operating Income forecast?
Projected CAGR
-33%

The compound annual growth rate of Basilea Pharmaceutica AG's operating income for the next 4 years is -33%.

What is Basilea Pharmaceutica AG's Net Income forecast?
Projected CAGR
-36%

The compound annual growth rate of Basilea Pharmaceutica AG's net income for the next 4 years is -36%.

Back to Top